Skip to main content

Table 2 The clinicopathological characteristics of these patients with recurrent HGSC

From: LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT signaling pathway

PatientFIGO stageRecurrent siteRecurrence interval (months)Recurrent lesions obtained for IHCMethod used to obtain specimensCurrent status
1IVBBrain10Pelvic massesOpen-abdominal surgeryDOD
2IIIBPelvic cavity18RectumOpen-abdominal surgeryDOD
3IIICPelvic/abdominal cavity29Transverse colonOpen-abdominal surgeryDOD
4IIICPelvic cavity11Pelvic massesOpen-abdominal surgeryDOD
5IIIBPelvic cavity45Pelvic massesOpen-abdominal surgeryDOD
6IIICPelvic cavity21Pelvic massesOpen-abdominal surgeryDOD
7IIIBLymph nodes18Inguinal lymph nodesBiopsyAWD
8IIICLymph nodes20Supraclavicular lymph nodesBiopsyDOD
9IIAPelvic cavity32Pelvic massesOpen-abdominal surgeryAWD
10IVBLymph nodes6Inguinal lymph nodesBiopsyDOD
11IIIBPelvic/abdominal cavity25Right colonOpen-abdominal surgeryAWD
12IIIBPelvic/abdominal cavity47Transverse colonOpen-abdominal surgeryAWD
  1. HGSC high-grade sercous carcinoma, FIGO International Federation of Gynecology and Obstetrics, IHC immunohistochemistry, DOD die of disease, AWD alive with disease